Comments for RBlog http://www.reportbuyer.com/blog Sharing intelligence Wed, 07 Jan 2009 20:43:45 +0000 http://wordpress.org/?v=2.2 Comment on Hovis’ Relaunch Set to Earn Them More Dough by Internet Marketing http://www.reportbuyer.com/blog/hovis%e2%80%99-relaunch-set-to-earn-them-more-dough/#comment-284171 Internet Marketing Wed, 12 Nov 2008 07:35:53 +0000 http://www.reportbuyer.com/blog/hovis%e2%80%99-relaunch-set-to-earn-them-more-dough/#comment-284171 This blog Is very informative , I am really pleased to post my comment on this blog . It helped me with ocean of knowledge so I really belive you will do much better in the future . Good job web master . This blog Is very informative , I am really pleased to post my comment on this blog . It helped me with ocean of knowledge so I really belive you will do much better in the future . Good job web master .

]]> Comment on Credit Card Fraud Reaches Record High of £500million by international credit card http://www.reportbuyer.com/blog/credit-card-fraud-reaches-record-high-of-500million/#comment-282391 international credit card Wed, 05 Nov 2008 23:42:51 +0000 http://www.reportbuyer.com/blog/credit-card-fraud-reaches-record-high-of-500million/#comment-282391 crazy how much money has been lost to fraud. thats why its so important to use a company that has some reliable form of credit card prevention. -jack crazy how much money has been lost to fraud. thats why its so important to use a company that has some reliable form of credit card prevention.
-jack

]]> Comment on UK Energy Retail: EDF/BE Merger Will Dominate, But Not Monopolise by pawseries http://www.reportbuyer.com/blog/uk-energy-retail-edfbe-merger-will-dominate-but-not-monopolise/#comment-281421 pawseries Thu, 30 Oct 2008 10:47:26 +0000 http://www.reportbuyer.com/blog/uk-energy-retail-edfbe-merger-will-dominate-but-not-monopolise/#comment-281421 I thought it was good I thought it was good

]]> Comment on Organic Products sector Fastest Growing in the North American Cosmetics Industry by organic towels http://www.reportbuyer.com/blog/organic-products-sector-fastest-growing-in-the-north-american-cosmetics-industry/#comment-281221 organic towels Tue, 28 Oct 2008 19:44:47 +0000 http://www.reportbuyer.com/blog/organic-products-sector-fastest-growing-in-the-north-american-cosmetics-industry/#comment-281221 Here we have organics towels, we produced as per strict organic standards , its purely cotton, its very impressive in health prospective, once try this product never forgotable we have different products , its online shopping shop securely Here we have organics towels, we produced as per strict organic standards ,
its purely cotton, its very impressive in health prospective, once try this
product never forgotable we have different products , its online shopping
shop securely

]]> Comment on Electricity could be Generated from Waste Food by Biofuelsimon http://www.reportbuyer.com/blog/electricity-could-be-generated-from-waste-food/#comment-273701 Biofuelsimon Fri, 24 Oct 2008 08:56:58 +0000 http://www.reportbuyer.com/blog/electricity-could-be-generated-from-waste-food/#comment-273701 There is a reasonable amount of waste food that could be used to produce biofuels. Digesters are one part of the answer perhaps. Another useful part could be the use of pyrolysis to convert the remaining biomass into gasses. These gases could be burned directly (like old fashioned town gas from coal) or converted into liquid fuel. There would still be the problem of disposing of the ash from this process but the volume would be considerably smaller than the volume of landfill. Such a two-pronged attack on the situation would yield more biofuel than simply digesting and would reduce volume. There is a reasonable amount of waste food that could be used to produce biofuels. Digesters are one part of the answer perhaps. Another useful part could be the use of pyrolysis to convert the remaining biomass into gasses. These gases could be burned directly (like old fashioned town gas from coal) or converted into liquid fuel. There would still be the problem of disposing of the ash from this process but the volume would be considerably smaller than the volume of landfill. Such a two-pronged attack on the situation would yield more biofuel than simply digesting and would reduce volume.

]]> Comment on Insurance Market Clear Winner as India’s Economy Goes from Strength to Strength by Rakhesh http://www.reportbuyer.com/blog/insurance-market-clear-winner-as-indias-economy-goes-from-strength-to-strength/#comment-263071 Rakhesh Tue, 14 Oct 2008 20:28:52 +0000 http://www.reportbuyer.com/blog/insurance-market-clear-winner-as-indias-economy-goes-from-strength-to-strength/#comment-263071 Thank You for this info. I look forward to more for sharing the same. Thank You for this info. I look forward to more for sharing the same.

]]> Comment on Battle for HIV drug market share getting fiercer - maybe too fierce for some by Jack http://www.reportbuyer.com/blog/battle-for-hiv-drug-market-share-getting-fiercer-maybe-too-fierce-for-some/#comment-261111 Jack Sat, 11 Oct 2008 03:39:43 +0000 http://www.reportbuyer.com/blog/battle-for-hiv-drug-market-share-getting-fiercer-maybe-too-fierce-for-some/#comment-261111 Individual therapies for HIV are incredibly expensive, one site I found useful for looking at current AIDS Drugs. http://www.aidsdrugsonline.com Individual therapies for HIV are incredibly expensive, one site I found useful for looking at current AIDS Drugs.

http://www.aidsdrugsonline.com

]]> Comment on Iran’s biggest motor manufacturer set to launch special car for women by Car Rental Switzerland http://www.reportbuyer.com/blog/irans-biggest-motor-manufacturers-set-to-launch-special-car-for-women/#comment-260921 Car Rental Switzerland Fri, 10 Oct 2008 11:11:47 +0000 http://www.reportbuyer.com/blog/irans-biggest-motor-manufacturers-set-to-launch-special-car-for-women/#comment-260921 Hi, nice site and good news to biggest motor manufacturer set to launch special car for women we got more information from this site. Really it is very nice site, good keep up it........ Hi,

nice site and good news to biggest motor manufacturer set to launch special car for women we got more information from this site. Really it is very nice site, good keep up it……..

]]> Comment on Fuel Cards Under Threat from Visa and Mastercard by steve clarke http://www.reportbuyer.com/blog/fuel-cards-under-threat-from-visa-and-mastercard/#comment-258341 steve clarke Mon, 06 Oct 2008 11:00:46 +0000 http://www.reportbuyer.com/blog/fuel-cards-under-threat-from-visa-and-mastercard/#comment-258341 One of the main points you mention in the piece is that fulcards can only be used for fuel and oil products, far from being a disadvantage this is one of the key selling points that we as fuel card suppliers use. Most fleet managers are looking for ways to control their costs and to increase security. With a commerical rate fuelcard like those supplied by ourselves, companies can purchased fuel at a fixed weekly price, anywhere in the UK on one of our networks. The fleet manager can be securee in the knowledge that the card can ONLY be used for fuel, unlike a credit card which can be "miss-used" to buy snacks and worse. Also fuel cards unlike credit and debit cards awork on a closed "network". They do not contain any of the customers banking information so if lost or stolen are far kore secure than a credit card, as they cannot be used to obtain funds from the customers bank account or to steal the custoemrs identity. One of the main points you mention in the piece is that fulcards can only be used for fuel and oil products, far from being a disadvantage this is one of the key selling points that we as fuel card suppliers use.

Most fleet managers are looking for ways to control their costs and to increase security. With a commerical rate fuelcard like those supplied by ourselves, companies can purchased fuel at a fixed weekly price, anywhere in the UK on one of our networks.

The fleet manager can be securee in the knowledge that the card can ONLY be used for fuel, unlike a credit card which can be “miss-used” to buy snacks and worse.

Also fuel cards unlike credit and debit cards awork on a closed “network”. They do not contain any of the customers banking information so if lost or stolen are far kore secure than a credit card, as they cannot be used to obtain funds from the customers bank account or to steal the custoemrs identity.

]]> Comment on UK Watchdog NICE Turns Down Four New Kidney Cancer Drugs by natalia http://www.reportbuyer.com/blog/uk-watchdog-nice-turns-down-four-new-kidney-cancer-drugs/#comment-234261 natalia Mon, 22 Sep 2008 10:56:20 +0000 http://www.reportbuyer.com/blog/uk-watchdog-nice-turns-down-four-new-kidney-cancer-drugs/#comment-234261 Data from a Phase II study of GlaxoSmithKline's Tykerb in head and neck cancer point to the potential for it to achieve expansion beyond the breast cancer market. Phase III development of the drug in the adjuvant head and neck cancer setting could prove to be more successful than an initial launch in the advanced/metastatic setting, where competition from Erbitux is likely to restrict sales. In the randomized Phase II study, 107 patients with previously untreated locally advanced squamous cell carcinoma of the head and neck (SCCHN) received either Tykerb (lapatinib; GlaxoSmithKline) or a placebo before treatment with standard platinum-based chemotherapy and radiotherapy. The results showed a statistically significant reduction in tumor cell proliferation in the Tykerb arm of the study (-8% vs -2.7% in the placebo arm, p=0.039). In 88 patients who underwent radiological analysis, the overall response rate was higher in the Tykerb arm than in the placebo arm (86% vs 63%) and the complete response rate was also higher in the Tykerb arm (28% vs 7%). However, GlaxoSmithKline did not state whether the difference in response rates reached statistical significance. Tykerb is an orally available small molecule that inhibits two key receptors associated with tumor growth: EGFR (ErbB1) and HER2 (ErbB2). A number of tumors show overexpression of at least one of these receptors, including SCCHN, where it is associated with a poor prognosis. Tykerb is approved in the US and EU in combination with Xeloda (capecitabine; Roche) for the treatment of advanced or metastatic HER2-positive breast cancer which has progressed following treatment with Herceptin (trastuzumab; Genentech/Roche). Erbitux (cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono), a monoclonal antibody which also targets EGFR, is the only targeted therapy available for head and neck cancer, and is approved in the US and EU for advanced/metastatic SCCHN. Erbitux’s first-to-market advantage and its established status as standard-of-care could restrict the uptake of other targeted therapies commercialized for advanced/metastatic SCCHN. It appears likely that GlaxoSmithKline does not initially intend for Tykerb to compete directly with Erbitux in locally advanced/metastatic SCCHN. Instead, it has launched a Phase III study evaluating Tykerb plus concurrent chemotherapy/radiotherapy in the adjuvant setting in patients who have undergone surgical resection (the MAINTYNANCE trial). If Tykerb is successful in this Phase III trial, it could achieve considerable market penetration in this area, given the lack of competition from other approved targeted therapies. However, while the reported Phase II results for Tykerb in locally advanced SCCHN suggest promising activity in this tumor type, it is far from certain whether this will translate into meaningful efficacy in the adjuvant setting. Data from a Phase II study of GlaxoSmithKline’s Tykerb in head and neck cancer point to the potential for it to achieve expansion beyond the breast cancer market. Phase III development of the drug in the adjuvant head and neck cancer setting could prove to be more successful than an initial launch in the advanced/metastatic setting, where competition from Erbitux is likely to restrict sales.
In the randomized Phase II study, 107 patients with previously untreated locally advanced squamous cell carcinoma of the head and neck (SCCHN) received either Tykerb (lapatinib; GlaxoSmithKline) or a placebo before treatment with standard platinum-based chemotherapy and radiotherapy. The results showed a statistically significant reduction in tumor cell proliferation in the Tykerb arm of the study (-8% vs -2.7% in the placebo arm, p=0.039). In 88 patients who underwent radiological analysis, the overall response rate was higher in the Tykerb arm than in the placebo arm (86% vs 63%) and the complete response rate was also higher in the Tykerb arm (28% vs 7%). However, GlaxoSmithKline did not state whether the difference in response rates reached statistical significance.

Tykerb is an orally available small molecule that inhibits two key receptors associated with tumor growth: EGFR (ErbB1) and HER2 (ErbB2). A number of tumors show overexpression of at least one of these receptors, including SCCHN, where it is associated with a poor prognosis. Tykerb is approved in the US and EU in combination with Xeloda (capecitabine; Roche) for the treatment of advanced or metastatic HER2-positive breast cancer which has progressed following treatment with Herceptin (trastuzumab; Genentech/Roche).

Erbitux (cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono), a monoclonal antibody which also targets EGFR, is the only targeted therapy available for head and neck cancer, and is approved in the US and EU for advanced/metastatic SCCHN. Erbitux’s first-to-market advantage and its established status as standard-of-care could restrict the uptake of other targeted therapies commercialized for advanced/metastatic SCCHN.

It appears likely that GlaxoSmithKline does not initially intend for Tykerb to compete directly with Erbitux in locally advanced/metastatic SCCHN. Instead, it has launched a Phase III study evaluating Tykerb plus concurrent chemotherapy/radiotherapy in the adjuvant setting in patients who have undergone surgical resection (the MAINTYNANCE trial). If Tykerb is successful in this Phase III trial, it could achieve considerable market penetration in this area, given the lack of competition from other approved targeted therapies. However, while the reported Phase II results for Tykerb in locally advanced SCCHN suggest promising activity in this tumor type, it is far from certain whether this will translate into meaningful efficacy in the adjuvant setting.

]]>